scholarly journals Stability of Generic Formulations of Bortezomib 1.0 and 2.5 mg/mL in Vials and Syringes Stored at 4°C and Room Temperature (23°C or 25°C)

2021 ◽  
Vol 74 (1) ◽  
Author(s):  
Shirley Law ◽  
Flay Charbonneau ◽  
John Iazzetta ◽  
William Perks ◽  
Nathan H Ma ◽  
...  
Keyword(s):  
Linear Regression ◽  
Multiple Linear Regression ◽  
Room Temperature ◽  
Degradation Products ◽  
Méthode Analytique ◽  
Published Data ◽  
Initial Concentration ◽  
Solution Saline ◽  
The Stability ◽  
Liquid Chromatographic

Background: The availability of generic versions of bortezomib raises questions about the reliability of extrapolating stability data from one brand to another. Objective: To evaluate the stability of bortezomib formulations available from Janssen, Teva Canada, Actavis Pharma, Dr. Reddy’s Laboratories, Apotex, and MDA, reconstituted with 0.9% sodium chloride (normal saline) to produce solutions of either 1.0 or 2.5 mg/mL and stored over at least 21 days under refrigeration (4°C) or at room temperature (either 23°C or 25°C) in the manufacturer’s original glass vials or in polypropylene syringes. Methods: On study day 0, solutions with concentration 1.0 mg/mL or 2.5 mg/mL of the Teva, Actavis, Dr. Reddy’s, Apotex, and MDA generic formulations were prepared. Three units of each type of container (glass vials and syringes) were stored at 4°C and 3 units at room temperature. Concentration and physical inspection were completed on at least 8 study days (including day 0) over a 21- to 84-day study period. Bortezomib concentrations were determined by a validated stability-indicating liquid chromatographic method with ultraviolet detection. The end point of these studies was the time to reach 90% of the initial concentration (T-90) with 95% confidence, which is expressed as “T-9095%CI”, where CI refers to the confidence interval. In addition to estimating the T-9095%CI, differences in stability among products from all manufacturers were compared using multiple linear regression. Previously published data for the Janssen product were included in the overall comparisons. Results: In all of the studies, the analytical method separated degradation products from bortezomib, such that the concentration of bortezomib was measured specifically, accurately (deviations < 2.5%), and reproducibly (average replicate error 2.5%). During all studies, solutions retained more than 94% of the initial concentration at 4°C. The T-9095%CI exceeded the study period for all formulations under all combinations of concentration, container, and temperature, except the 84-day study for the MDA product. Multiple linear regression showed no significant differences among manufacturers (p = 0.57). Conclusions: In this study, formulations of bortezomib currently marketed in Canada (by Janssen, Teva Canada, Actavis Pharma, Dr. Reddy’s Laboratories, Apotex, and MDA) were pharmaceutically equivalent and interchangeable. Given that there was no difference in stability related to manufacturer, nominal concentration, or container, we conclude that these formulations are physically and chemically stable for at least 35 days under refrigeration and at least 25 days at room temperature.  RÉSUMÉ Contexte : La disponibilité de versions génériques de bortezomib soulève des questions relatives à la fiabilité de l’extrapolation des données concernant la stabilité d’une marque à l’autre. Objectif : Évaluer la stabilité des formules de bortezomib de Janssen, de Teva Canada, d’Actavis Pharma, des Laboratoires du Dr Reddy, d’Apotex et de MDA, reconstituées avec 0,9 % de chlorure de sodium (solution saline normale) pour produire des solutions de 1 ou de 2,5 mg/mL et réfrigérées au moins 21 jours à 4 °C ou à température ambiante (23 °C ou 25 °C), dans des fioles en verre du fabricant ou dans des seringues en polypropylène. Méthodes : La préparation des solutions avec une concentration de 1 mg/mL ou 2,5 mg/mL des formules génériques de Teva, d’Actavis, du Dr Reddy, d’Apotex et de MDA a eu lieu le jour 0 de l’étude. Trois unités de chaque contenant (fioles en verre et seringues) étaient stockées à 4 °C et 3 unités, à température ambiante. L’inspection de la concentration et l’inspection physique ont été réalisées pendant au moins 8 jours (y compris le jour 0) de l’étude qui a duré de 21 à 84 jours. Les concentrations de bortezomib ont été déterminées par une méthode chromatographique liquide validée, indiquant la stabilité à l’aide d’une détection par rayons ultraviolets. Le point final de ces études était le temps nécessaire pour que le produit atteigne 90 % de la concentration initiale (T-90) avec un seuil de confiance de 95 %, exprimé par T-90IC 95 %, IC indiquant l’intervalle de confiance. En plus de l’estimation du T-90IC 95 %, les différences de stabilité des produits de tous les fabricants ont été comparées à l’aide d’une régression linéaire multiple. Les données publiées précédemment sur le produit Jansen sont incluses dans les comparaisons globales. Résultats : La méthode analytique de toutes les études qui ont été menées a séparé les produits de dégradation du bortezomib de telle manière que la concentration était mesurée de manière spécifique, précise (déviations < 2,5 %) et reproductible (erreur de réplique 2,5 %). Tout au long des études, les solutions ont retenu plus de 94 % de la concentration initiale à 4 °C. Le T-90IC 95 % de toutes les formules dans toutes les combinaisons de concentration, de contenant et de température, dépassait la durée des études, à l’exception du produit MDA dans l’étude de 84 jours. La régression linéaire multiple n’a indiqué aucune différence importante parmi les fabricants (p = 0,57). Conclusions : Dans cette étude, les formules de bortezomib actuellement commercialisées au Canada (par Janssen, Teva Canada, Actavis Pharma, les Laboratoires du Dr Reddy, Apotex et MDA) étaient équivalentes et interchangeables d’un point de vue pharmaceutique. Puisqu’aucune différence de stabilité, de concentration nominale ou de contenant liée à l’un ou l’autre des fabricants n’a été révélée, nous concluons que ces formules sont physiquement et chimiquement stables pendant au moins 35 jours sous réfrigération et au moins 25 jours à température ambiante.

scholarly journals Stability of Compounded Clozapine 25 mg/mL and 50 mg/mL Suspensions in Plastic Bottles

2021 ◽  
Vol 74 (3) ◽  
Author(s):  
Scott E Walker ◽  
Hanif Sachedina ◽  
Katia Bichar
Keyword(s):  
Room Temperature ◽  
Degradation Rate ◽  
Degradation Products ◽  
Reverse Phase ◽  
Measured Concentration ◽  
Unknown Compound ◽  
Initial Concentration ◽  
Liquid Chromatographic Method ◽  
The Stability ◽  
Liquid Chromatographic

Background: Clozapine oral suspension is not commercially available in Canada but is required for administration to patients who cannot swallow intact tablets. Objective: To evaluate the stability of 25 mg/mL and 50 mg/mL clozapine suspensions prepared in a 50:50 mixture of methylcellulose gel 1% and Oral Syrup (flavoured syrup vehicle, Medisca Pharmaceutique Inc) and stored in amber glycol-modified polyethylene terephthalate (PET-G) bottles over 120 days at 4°C and 25°C. Methods: This study used a validated reverse-phase stability-indicating liquid chromatographic method capable of quantifying clozapine, 3 known degradation compounds, a known impurity, and an unknown compound. Three separate batches of 25 mg/mL and 50 mg/mL clozapine suspensions were prepared, divided into 100-mL aliquots, and stored in 120-mL PET-G bottles. Half of the bottles from each concentration were stored at room temperature (20°C to 25°C) and the other half were stored in the refrigerator (2°C to 8°C). On study days 0, 28, 60, 90, and 120, concentrations of clozapine, each of the 3 known clozapine degradation products, a known impurity, and an unknown compound were determined. Results: When suspensions were stored in PET-G containers at room temperature or under refrigeration for 120 days, the concentration of clozapine remained above 95% of initial concentration, and the measured concentration of degradation products and impurities did not exceed the 0.5% limits set by regulatory authorities worldwide. The proportion of the initial concentration of clozapine remaining on day 120, based on fastest degradation rate with 95% confidence (1-sided), exceeded 92%, and the only degradation product found (clozapine lactam, 0.2%) and an unknown impurity (0.2%) also did not exceed allowable limits. Conclusions: Compounded clozapine suspensions of 25 mg/mL and 50 mg/mL can be stored in amber PET-G containers for up to 120 days after preparation with storage at room temperature or under refrigeration. RÉSUMÉ Contexte : La clozapine en suspension orale n’est pas disponible sur le marché canadien, mais elle est nécessaire pour les patients qui ne peuvent l’avaler sous forme de comprimé intact. Objectif : Évaluer la stabilité des suspensions de clozapine de 25 mg/mL et de 50 mg/mL, préparées dans un mélange 50:50 de gel méthylcellulose à 1 % et de Sirop Oral (véhicule de sirop aromatisé, MEDISCA) et conservées dans des flacons ambrés en polytéréphtalate d’éthylène modifié au glycol (PET-G) pendant 120 jours à des températures de 4°C et 25°C. Méthode : Cette étude a utilisé une méthode validée par chromatographie liquide indicatrice de stabilité en phase inverse pouvant quantifier la clozapine, trois composés de dégradation connus, une impureté connue et un composé inconnu. Trois lots séparés de suspensions de clozapine de 25 mg/mL et de 50 mg/mL ont été préparés, divisés dans des aliquotes de 100-mL et stockés dans des flacons en PET-G de 120-mL. La moitié des flacons de chaque concentration a été conservée à température ambiante (de 20°C à 25°C), et l’autre moitié au réfrigérateur (de 2°C à 8°C). Aux jours 0, 28, 60, 90 et 120 de l’étude, on a déterminé les concentrations de clozapine, celles de chacun des trois produits de dégradation de la clozapine, celles d’une impureté connue et d’un complexe inconnu. Résultats : Lorsque les suspensions étaient stockées dans des contenants en PET-G à température ambiante et réfrigérées pendant 120 jours, la concentration de clozapine demeurait au-dessus de 95 % de la concentration initiale; la concentration mesurée des produits de dégradation et des impuretés ne dépassait pas la limite de 0,5 % fixée par les autorités de règlementation mondiales. La proportion de concentration initiale de clozapine restante au 120e jour, sur la base du taux de dégradation le plus rapide avec un intervalle de confiance de 95 % (unilatéral), dépassait 92 %, et le seul produit de dégradation trouvé (clozapine lactam, 0,2 %) ainsi qu’une impureté inconnue (0,2 %) ne dépassaient pas non plus les limites autorisées. Conclusions : Les suspensions de clozapine composées de 25 mg/mL et de 50 mg/mL peuvent être conservées dans des contenants ambrés PET-G jusqu’à 120 jours après leur préparation, soit à température ambiante, soit dans un réfrigérateur.

Stability-Indicating Liquid Chromatographic Procedure for Determination of Allantoin in Cosmetic Lotion

1988 ◽  
Vol 71 (2) ◽  
pp. 290-294
Author(s):  
Ramesh J Trivedi
Keyword(s):  
Degradation Products ◽  
Glyoxylic Acid ◽  
Uv Detector ◽  
Stability Indicating ◽  
Assay Procedure ◽  
Relative Standard ◽  
The Stability ◽  
Chromatographic Parameters ◽  
Liquid Chromatographic

Abstract A sensitive, specific liquid chromatographic (LC) procedure was developed for determination of allantoin [(2,5-dioxo-4--imidaazolidinyl) urea or 5-ureidohydantion] in cosmetic lotion. A reverse-phase, ionsuppression mechanism separated allantoin from interfering constituents of the sample matrix, and the compound was determined with a UV detector at 240 nm with a sensitivity limit of ((.20 mg/mL. The chromatographic parameters were optimized for retention time, efficiency, and relative response to the analyte. The assay procedure was validated with spiked laboratory-prepared samples at 100 ± 15% levels. An average recovery of 99.4% with a relative standard deviation of 1.5% (n = 7) was obtained. The stability-indicating characteristics of the method were established by recovery study (99.8%) of samples spiked with known degradation products (urea, allantoic acid, and glyoxylic acid).

scholarly journals Biodegradation and Biosurfactant Production by Agrobacterium tumefaciens Utilizing Weathered Mineral base Oil

2012 ◽  
Vol 6 (1) ◽  
pp. 45-55
Author(s):  
Reem Waleed Yonis
Keyword(s):  
Agrobacterium Tumefaciens ◽  
Room Temperature ◽  
Biosurfactant Production ◽  
Production Medium ◽  
Optimum Conditions ◽  
Base Oil ◽  
Initial Concentration ◽  
Weathered Oil ◽  
The Stability ◽  
Mineral Base

ptimum condition of biodegradation and biosurfactant production from spilled weathered base oil by Agrobacterium tumefaciens was studied in batch culture. Results showed that the optimum conditions for biosurfactant production was at pH7, temperature 30°C, incubation period 72h, and addition of weathered oil in a concentration of 3%, which yielded high biosurfactant production reached 6.6 g/l. The results also showed capability of isolate to degrade 70% of initial concentration of weathered oil 3%. Some characteristics and nature of produced biosurfactant was studied, the results showed that the biosurfactant is white to yellow in color, and viscous at room temperature, and needs little heating to be prepared in aqueous solution, insoluble in water and some organic solvents. The results also indicated higher stability of produced biosurfactant at neutral pH, and the stability decreased at pH less than 5 and up to 9, while the best stability of produced biosurfactant was at 30 and 40˚C. The addition of crude biosurfactant in concentration 20mg/l to the production medium lead to stimulate the isolate for uptake of weathered oil and increase biosurfactant production, while the biomass production did not affected significantly.

scholarly journals Studies on Paliperidone in OROS Tablets: Extraction Procedure and Chromatographic Analysis

2012 ◽  
Vol 2012 ◽  
pp. 1-9 ◽  
Author(s):  
Fábio Barbosa ◽  
Luciano Mantovani ◽  
Cássia V. Garcia ◽  
Andreas S. L. Mendez
Keyword(s):  
Oral Delivery ◽  
Degradation Products ◽  
Extraction Procedure ◽  
Reversed Phase ◽  
Forced Degradation ◽  
Phase System ◽  
Stability Indicating ◽  
Ultrasonic Bath ◽  
The Stability ◽  
Liquid Chromatographic

A stability-indicating liquid chromatographic (LC) method was studied for the determination of paliperidone in osmotic-controlled release oral delivery system (OROS) tablets. A tablet extraction procedure was developed by testing the efficiency of solvents (water, HCl, NaOH, acetonitrile, methanol) and techniques (ultrasonic bath, magnetic stirrer), and evaluating the release of the drug with respect to time. A forced degradation study was conducted to demonstrate the stability-indicating power of the method. Chromatographic separation was achieved using an isocratic elution in a reversed-phase system with a mobile phase prepared from a mixture of phosphate buffer and acetonitrile. The use of an ultrasonic bath demonstrated paliperidone release from OROS tablets in a total time of 60 min. Verifying the efficiency of the chromatographic procedure, the theoretical plates (N=12634.21) and tailing factor (tf=1.31) were constant during repeated injections. The retention time of paliperidone was 4.8 min, and the method was validated within the concentration range of 10–50 μg mL-1 (r=0.9999). Adequate reproducibility (RSD% = 0.30–0.59), interday precision (RSD%=1.81), and accuracy were obtained. The proposed method was successfully applied to paliperidone determination in the presence of degradation products, and an efficient extraction procedure from the OROS tablets was developed.

scholarly journals Administration of Intravenous Ascorbic Acid—Practical Considerations for Clinicians

Nutrients ◽  
2019 ◽  
Vol 11 (9) ◽  
pp. 1994 ◽  
Author(s):  
Scott E. Walker ◽  
John Iazzetta ◽  
Shirley Law ◽  
Salmaan Kanji ◽  
Brigitte Bolduc ◽  
...  
Keyword(s):  
Ascorbic Acid ◽  
Initial Concentration ◽  
Solution Type ◽  
Liquid Chromatographic Separation ◽  
Degradation Rates ◽  
Intravenous Ascorbic Acid ◽  
The Stability ◽  
Liquid Chromatographic ◽  
Visual Changes ◽  
Require Data

Emerging data suggest that intravenous ascorbic acid (AA) may be beneficial in patients with sepsis. Clinicians require data on stability of diluted AA for safe administration. We evaluated the stability of AA diluted in normal saline (NS) or 5% dextrose in water (D5W) solutions over 14 days at 25 °C and at 4 °C, protected from light, using concentrations of 37 mg/mL and 77 mg/mL (Sandoz) and 40 mg/mL and 92 mg/mL (Mylan). We also assessed stability of a 40 mg/mL solution (Mylan) at 25 °C exposed to light for 75 h. Concentrations were measured using liquid chromatographic separation with ultraviolet light detection on days 0, 0.33, 1, 1.33, 2, 3, 4, 7, 10 and 14. By day 14, solutions at 4 °C retained >97.72% of the initial concentration; at 25 °C, solutions retained >88.02% of the initial concentration, but visual changes were evident after day 2. Multiple linear regression demonstrated that study day and temperature (p < 0.001) but not solution type (p = 0.519), concentration (p = 0.677) or manufacturer (p = 0.808) were associated with the percentage remaining. At 75 h, degradation rates were similar in solutions protected from vs. exposed to light. In conclusion, AA solutions are stable for at least 14 days at 4 °C, with protection from light.

scholarly journals Physicochemical Stability of Vancomycin at High Concentrations in Polypropylene Syringes

2019 ◽  
Vol 72 (5) ◽  
Author(s):  
Élise D’Huart ◽  
Jean Vigneron ◽  
Alexandre Charmillon ◽  
Igor Clarot ◽  
Béatrice Demoré
Keyword(s):  
High Performance ◽  
Room Temperature ◽  
Physical Stability ◽  
Syringe Pump ◽  
High Concentration ◽  
Initial Concentration ◽  
Infusion Line ◽  
Severe Infections ◽  
High Concentrations ◽  
The Stability

ABSTRACTBackground: In severe infections, high-concentration vancomycin may be administered by continuous infusion. The dosage of vancomycin may reach 60 mg/kg per day. Objectives: To study the feasibility of preparing high-concentration vancomycin solutions (40 to 83.3 mg/mL), to study the effect of an electric syringe pump on the physical stability of high-concentration vancomycin, and to study the stability of vancomycin 62.5 and 83.3 mg/mL in 0.9% sodium chloride (0.9% NaCl) or 5% dextrose in water (D5W) with storage up to 48 h at room temperature. Methods: The following sets of syringes were prepared: (1) 4 syringes of vancomycin in 0.9% NaCl for each of 5 concentrations between 40 and 83.3 mg/mL (total 20 syringes); (2) 6 syringes at 83.3 mg/mL in 0.9%NaCl and 6 syringes at 83.3 mg/mL in D5W; and (3) 30 syringes at 83.3 mg/mL in D5W. Visual inspection was performed for all 3 syringe sets, and subvisual inspection for sets 1 and 2 (for periods of 24 h for set 1 and 48 h for sets 2 and 3). One syringe of vancomycin 83.3 mg/mL with each solvent was inserted into an electric syringe pump, and samples from the infusion line and collected after transit through the pump were inspected visually. Chemical stability was evaluated by high-performance liquid chromatography, and physical stability, pH, and osmolality were investigated. Results: For all sets of syringes, no physical modification was observed over time, nor were any changes observed after transit through the electric syringe pump. In 0.9% NaCl, vancomycin 62.5 and 83.3 mg/mL retained more than 90% of the initial concentration after 48 and 24 h, respectively; however, for the 83.3 mg/mL solution, precipitate was visible after 48 h. In D5W, vancomycin at 62.5 and 83.3 mg/mL retained more than 90%of the initial concentration after 48 h. Conclusion: It was feasible to prepare high-concentration solutions of vancomycin. The electric syringe pump did not cause any precipitation. Vancomycin in D5W at 62.5 and 83.3 mg/mL was stable over 48 h at room temperature. Precipitation occurred in 0.9% NaCl. D5W is therefore recommended as the solvent for this drug.RÉSUMÉContexte : En cas d’infection grave, de la vancomycine à forte concentration peut être administrée par perfusion continue à une dose pouvant atteindre 60 mg/kg par jour. Objectifs : Mener une étude de faisabilité portant sur la préparation de solutions de vancomycine à forte concentration (de 40 à 83,3 mg/mL); étudier l’effet d’un pousse-seringue électrique sur la stabilité physique de la vancomycine à forte concentration; et étudier la stabilité de la vancomycine (62,5 et 83,3 mg/mL) dans une solution de chlorure de sodium à 0,9 % (NaCl à 0,9 %) ou dans une solution aqueuse de dextrose à 5 % (D5W) après 48 h à la température ambiante.Méthodes : Trois ensembles de seringues ont été préparés : (1) quatre seringues de vancomycine dans une solution de NaCl à 0,9 %, à chacune des cinq concentrations comprises entre 40 et 83,3 mg/mL (20 seringues au total); (2) six seringues à 83,3 mg/mL dans une solution de NaCl à 0,9 % et six seringues à 83,3 mg/mL dans une solution de D5W; et (3) 30 seringues à 83,3 mg/mL dans une solution de D5W. Une inspection visuelle des trois ensembles de seringues et une inspection « sous-visuelle » des ensembles 1 et 2 ont eu lieu (période de 24 h pour l’ensemble 1 et de 48 h pour les ensembles 2 et 3). Une seringue contenant de la vancomycine à 83,3 mg/mL mélangée à chaque solvant a été insérée dans un pousse-seringue électrique, et les échantillons prélevés dans le tube de perfusion et ceux recueillis après leur passage dans la pompe ont été inspectés visuellement. La stabilité chimique a été évaluée par chromatographie liquide à haute performance et la stabilité physique, le pH ainsi que l’osmolalité ont eux aussi été étudiés. Résultats : Les trois ensembles de seringues n’ont présenté aucune modification physique avec le temps. Aucun changement n’a non plus été observé après le passage dans le pousse-seringue électrique. Dans la solution de NaCl à 0,9 %, la vancomycine à 62,5 et à 83,3 mg/mL a conservé plus de 90 % de sa concentration initiale respectivement après 48 et 24 h. Cependant, le précipité de la solution à 83,3 mg/mL était visible après 48 h. Dans la solution de D5W, la vancomycine à 62,5 et à 83,3 mg/mL a conservé plus de 90 % de sa concentration initiale après 48 h. Conclusion : La préparation de solutions de vancomycine à forte concentration est faisable. Le pousse-seringue électrique n’a pas causé de précipitation. La vancomycine dans la solution de D5W à 62,5 et à 83,3 mg/mL est restée stable pendant plus de 48 h à la température ambiante. Les précipitations se sont produites dans les solutions de NaCl à 0,9 %. On recommande donc la solution de D5W comme solvant pour ce médicament.

scholarly journals Stability Assessment of Cephradine Suspension Formulated in Bangladesh

2011 ◽  
Vol 3 (2) ◽  
pp. 383-391
Author(s):  
M. Z. Sultan ◽  
M. A. Mazid ◽  
M. A. Rashid
Keyword(s):  
Aqueous Medium ◽  
High Performance ◽  
Room Temperature ◽  
Chromatographic Method ◽  
Pharmaceutical Preparation ◽  
High Performance Liquid Chromatographic ◽  
Reversed Phase ◽  
Sodium Phosphate Buffer ◽  
The Stability ◽  
Liquid Chromatographic

Cephradine, one of the commonly used and widely prescribed antibiotics in Bangladesh, is usually formulated in the dosage forms of capsule, dry suspension and IV injection. The dry-suspension is instructed to re-disperse in pre-boiled cooled water before use. A reversed phase high performance liquid chromatographic method (HPLC) has been developed for determination of cephradine in pharmaceutical preparation. To study the stability of cephradine suspension formulated by Bangladeshi manufacturers in aqueous medium and buffer of different pHs at room temperature, a simple and rapid chromatographic method was developed using acetonitrile and monobasic sodium phosphate buffer as mobile phase in the ratio of 15:85 (v/v) over C-8 bonded silica at ambient temperature using a flow rate of 1.0 mL/min.  The study revealed that the potency of cephradine suspension was almost stable at room temperature up to 13 days in aqueous medium at pH between 4 and 5.Keywords: Cephradine; Suspension; HPLC; Potency; pH.© 2011 JSR Publications. ISSN: 2070-0237 (Print); 2070-0245 (Online). All rights reserved.doi:10.3329/jsr.v3i2.7024                J. Sci. Res. 3 (2), 383-391 (2011)

scholarly journals Stability of the Combination of Ceftazidime and Cephazolin in Icodextrin or PH Neutral Peritoneal Dialysis Solution

2014 ◽  
Vol 34 (2) ◽  
pp. 212-218 ◽  
Author(s):  
Rahul P. Patel ◽  
Madhur D. Shastri ◽  
Mohammad Bakkari ◽  
Troy Wanandy ◽  
Matthew D. Jose
Keyword(s):  
Peritoneal Dialysis ◽  
Body Temperature ◽  
High Performance ◽  
Room Temperature ◽  
Storage Conditions ◽  
Initial Concentration ◽  
Dialysis Solution ◽  
Different Temperatures ◽  
Colour Changes ◽  
The Stability

IntroductionThe objective of this study was to investigate the stability of ceftazidime and cephazolin in a 7.5% icodextrin or pH neutral peritoneal dialysis (PD) solution.MethodsCeftazidime and cephazolin were injected into either a 7.5% icodextrin or pH neutral PD bag to obtain the concentration of 125 mg/L of each antibiotic. A total of nine 7.5% icodextrin or pH neutral PD bags containing ceftazidime and cephazolin were prepared and stored at 1 of 3 different temperatures: 4°C in a domestic refrigerator; 25°C at room temperature; or 37°C (body temperature) in an incubator. An aliquot was withdrawn immediately before (0 hour) or after 12, 24, 48, 96, 120, 144, 168 and 336 hours of storage. Each sample was analyzed in duplicate for the concentration of ceftazidime and cephazolin using a stability-indicating high-performance liquid chromatography technique. Ceftazidime and cephazolin were considered stable if they retained more than 90% of their initial concentration. Samples were also assessed for pH, colour changes and evidence of precipitation immediately after preparation and on each day of analysis.ResultsCeftazidime and cephazolin in both types of PD solution retained more than 90% of their initial concentration for 168 and 336 hours respectively when stored at 4°C. Both of the antibiotics lost more than 10% of the initial concentration after 24 hours of storage at 25 or 37°C. There was no evidence of precipitation at any time under the tested storage conditions. Change in the pH and color was observed at 25 and 37°C, but not at 4°C.ConclusionPremixed ceftazidime and cephazolin in a 7.5% icodextrin or pH neutral PD solution is stable for at least 168 hours when refrigerated. This allows the preparation of PD bags in advance, avoiding the necessity for daily preparation. Both the antibiotics are stable for at least 24 hours at 25 and 37°C, permitting storage at room temperature and pre-warming of PD bags to body temperature prior to its administration.

scholarly journals Qualitative and Quantitative Reversed-Phase Liquid Chromatography of a New Bisisoxazolylnaphthoquinone

2002 ◽  
Vol 85 (2) ◽  
pp. 349-354
Author(s):  
Carola F Ferreyra ◽  
Cristina S Ortiz ◽  
María M de Bertorello
Keyword(s):  
Degradation Products ◽  
Reversed Phase ◽  
Reversed Phase Liquid Chromatography ◽  
Symmetry Factor ◽  
Phase Liquid ◽  
Internal Standardization ◽  
The Stability ◽  
Ph Range ◽  
Liquid Chromatographic ◽  
Decomposition Path

Abstract The main objective of this study was to develop and test the applicability of a sensitive, accurate, and precise liquid chromatographic (LC) method for evaluating the stability characteristics of a new bisisoxazolylnaphthoquinone, 2-(3,5-dimethyl-4-isoxazolylamino)-N-(3,5-dimethyl-4-isoxazolyl)-1,4-naphthoquinone-4-imine compound 1. The method was shown to be selective and stability-indicating. Isocratic elution with a mobile phase of methanol–water (75 + 25, v/v) on a reversed-phase column with UV detection at ambient temperature completely resolved compound 1 from its degradation products. The LC system was calibrated by plotting peak responses versus known concentrations of a reference standard by using an internal standardization procedure. Complete elution occurred after 12 min with a peak symmetry factor of 0.95 for the drug peak. The kinetic degradation of compound 1 was studied over a pH range of 0.88–14.00 to determine the kinetic parameters involved in its decomposition path in aqueous solution.

Sign in / Sign up

Export Citation Format

Share Document